๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection

โœ Scribed by Massimo Puoti; Antonella Zonaro; Antonella Ravaggi; Maria Grazia Marin; Filippo Castelnuovo; Elisabetta Cariani


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
566 KB
Volume
16
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


Hepatitis C virus RNA, anti-hepatitis C virus immune response and biochemical markers of liver injury were investigated in 17 patients with acute non-A, non-B hepatitis. At the first observation, 1 to 3 wk from the clinical onset, all patients had hepatitis C virus RNA in their serum, and most (15 of 17) were positive for second-generation anti-hepatitis C virus enzyme immunoassay. Follow-up serum samples were available for 10 patients. The rate of recombinant immunoblot assay-confirmed anti-hepatitis C virus enzyme immunoassay reactivities increased from 67% in the first 3 wk to 86% after 21 wk. Elevated ALT levels were associated with hepatitis C virus RNA positivity in most of cases, but the viral nucleic acid was also detected in sera with normal or slightly increased enzyme values. None of the single antibodies tested were related to hepatitis C virus RNA positivity or to the clinical phase of the infection. Therefore hepatitis C virus RNA determination might provide important additional information as compared with anti-hepatitis C virus markers, allowing earlier diagnosis, discrimination of active infection and, possibly, prognostic evaluation.


๐Ÿ“œ SIMILAR VOLUMES


Histological changes in hepatitis C viru
โœ Isabelle Moreau; Elizabeth Kenny-Walsh; Orla Crosbie; Liam J. Fanning ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 46 KB

We read with interest the article by Hoare et al. 1 published recently in HEPATOLOGY. Hoare et al. reported that patients who are seropositive aviremic for hepatitis C can be considered likely positive for the virus on the basis of histological changes. The retrospective study initially involved a r

Hepatitis C virus RNA in peripheral bloo
โœ T Chang; K Young; Y Yang; H Lei; H Wu ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 174 KB ๐Ÿ‘ 2 views

Hepatitis C virus (HCV) can infect peripheral blood mately 10 kb. 2 Acute posttransfusion hepatitis C mononuclear cells (PBMC) of patients with chronic HCV (PTHC) is followed by chronic hepatitis in about 50% infection. No data are available on PBMC testing for of the cases. Chronic hepatitis may al

Prevalence of hepatitis C virus antibodi
โœ Dr. M. Rapicetta; A. F. Attili; A. Mele; A. de Santis; P. Chionne; K. Cristiano; ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 554 KB

## Abstract Several studies had been carried out on antiโ€hepatitis C virus (HCV) prevalence in populations with blood exposure risks and in blood donors. New tests are now available which allow the inโ€ vestigation to extend to other parameters such as antibody type and HCVโ€RNA. In this study the p

IgM antibody to hepatitis C virus in acu
โœ Juan Antonio Quiroga; Marรญa Luz Campillo; Inmaculada Catillo; Javier Bartolomรฉ; ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 618 KB

To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patients with chronic non-A, non-B hepatitis for IgG and IgM antibody to hepatitis C virus. IgG antibody to hepatitis C virus w

Lack of correlation between hepatitis C
โœ L. Benvegnรน; P. Pontisso; D. Cavalletto; F. Noventa; L. Chemello; A. Alberti ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 188 KB ๐Ÿ‘ 1 views

tions (PCR), as described in later paragraphs. When virus sequences were amplifiable by this technique, they were further characterized for genotype and subtype, as described in later paragraphs in detail. Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; ALT, alanine Follow-Up.